Syntis Bio's oral obesity pill shows early satiety-hormone signal in 32 healthy adults
A single-dose Phase 1 cohort found no serious side effects and sharp hormone shifts, but the trial was built to test safety, not weight loss, leaving the efficacy question to the pending multiple-dose data.
Executive Summary
- A Phase 1 single-dose cohort of Syntis Bio's oral obesity candidate showed no serious side effects and produced hormone changes consistent with the mechanism the company is testing, though the study was not designed to measure weight loss.
- The sponsor frames the hormone data as evidence of efficacy, but the trial's registered primary endpoint is safety and tolerability, not a weight-loss or efficacy measure, so the framing outruns what this cohort can establish.
- A separate multiple-dose cohort in overweight and obese adults has finished enrolling and will generate the first data in the intended patient population, later this year.
- SYNT-101 enters an obesity landscape already anchored by approved and late-stage GLP-1 receptor agonists, meaning any future efficacy data will be read against an established benchmark rather than a blank field.
What was tested
The randomized, double-blind, placebo-controlled single ascending dose (SAD) portion of the Phase 1/1b SYNTIETY-1 trial dosed 32 healthy adult volunteers across four cohorts, from 857 mg to 3,428 mg, or one to four tablets. The trial's registered primary endpoint is safety evaluation, with pharmacokinetic measures as secondary endpoints; it was not designed to measure weight loss or a clinical obesity outcome. SYNT-101 is designed as a once-daily oral tablet intended to replicate metabolic effects associated with bariatric surgery through a transient, self-clearing synthetic lining of the small intestine. NCT07307274+1A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight AdultsNCT07307274Syntis Bio Reports Positive Initial Phase 1/1b Single Ascending Dose Data for SYNT-101, Supporting its Novel Approach to Obesity TreatmentJul 16, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The safety and hormone data
Syntis Bio said SYNT-101 caused no discontinuations, no serious adverse events, and no related gastrointestinal adverse events at any dose level; the only treatment-related adverse event was mild, self-limited hypoglycemia during oral glucose tolerance testing. Continuous glucose monitoring showed a 17% reduction in glucose absorption from baseline during that testing, and single-tablet dosing was linked to a 58% increase in total GLP-1, a 125% increase in peptide YY, a 21% reduction in ghrelin, and a 100% increase in leptin. Chief Development Officer David Rosenbaum said the data "validate SYNT-101's core mechanism of action, affirm its potential for best-in-class tolerability among weight management therapies, and demonstrate early indications of efficacy". SyntisSyntis Bio Reports Positive Initial Phase 1/1b Single Ascending Dose Data for SYNT-101, Supporting its Novel Approach to Obesity TreatmentJul 16, 2026
The framing gap
That statement claims efficacy signals from a cohort of healthy volunteers dosed once, in a trial whose registered goal was to establish safety and pharmacokinetics, not to demonstrate a weight-loss effect. Hormone shifts after a single dose are associative evidence that the drug engages its intended pathway; they are not a measured weight or metabolic outcome, and the trial as designed cannot produce one from this cohort. The characterization has been flagged as emphasizing findings the study was not built to test. NCT07307274+1A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight AdultsNCT07307274Syntis Bio Reports Positive Initial Phase 1/1b Single Ascending Dose Data for SYNT-101, Supporting its Novel Approach to Obesity TreatmentJul 16, 2026
What comes next
Syntis Bio said enrollment in the 28-day multiple ascending dose (MAD) cohort, which will test SYNT-101 in overweight or obese patients rather than healthy volunteers, is now complete, with data expected later in 2026. That cohort will be the first to test the drug in its intended population and the first that could speak to a metabolic or weight effect rather than tolerability alone. The trial's overall primary completion date is registered as October 1, 2026. Syntis+1Syntis Bio Reports Positive Initial Phase 1/1b Single Ascending Dose Data for SYNT-101, Supporting its Novel Approach to Obesity TreatmentJul 16, 2026A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight AdultsNCT07307274
The competitive field
Obesity drug development is dense with GLP-1 receptor agonists already at Phase 3 or Phase 4, including Eli Lilly's tirzepatide and retatrutide, Novo Nordisk's semaglutide and CagriSema, none of which share SYNT-101's target or mechanism class and none of which are formal comparators to this trial. SYNT-101's target and mechanism class are not established in available trial data, so no isolation or first-in-class claim can be drawn; the asset is best characterized by its modality, an oral tablet designed to alter nutrient sensing in the small intestine, and its early phase relative to a field where multiple GLP-1-class drugs are already commercial or in late-stage testing. Any future efficacy data from SYNT-101 will be read against that established benchmark rather than an open field. NCT07307274A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight AdultsNCT07307274
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.